We have compared several combinations of enhancers and promoters 1n expressing the chlorarophenical acetyl transferase gene In transient assays, 1n mouse Cl27, the most widely used host cell for the bovine papilloma virus (BPV) expression vector. Of the various combinations tested, the unit comprised of the SV40 enhancer and adenovirus type 2 major late promoter (NLP) was the most active 1n BPV transformed C127 cells. We further demonstrate that untransformed and BPV transformed C127 cells respond differently to the various enhancer/promoter combinations tested.
cytomegalovirus (HCHV) enhancer and SV40 promoter (pC4.24). pSV CAT was digested with Ace 1, which cuts within the pBR322 sequence 179 bp upstream from the SV40 early promoter, and the Ace I termini were made blunt with Klenow fragment. Subsequent digestion with H1nd III removed the SV40 early enhancer-promoter unit from pSV 2 CAT. The HCHV enhancer with the associated SV40 promoter was Isolated from pC4 by digesting with Nae I (SV40 nucleotide no.348) and Hind III (SV40 nudeotide no.5171) followed by agarose gel purification of the resultant 453 bp fragment. Ugation of the purified fragments resulted 1n the production of pCH-SV-CAT.
PHLP-CAT. This plasmid consists of pHL2d. adenovirus major late promoter (MLP), and the CAT gene assembled sequentially as follows: The BaraH I site of pML2d (25), was converted to an Xho I site with synthetic linkers, resulting 1n pl30-l (26).
A synthetic oligonucleotide of the sequence, AATT6ATATCTCTAGACAGC1GTCTA6AGATATC, specifying restriction sites EcoR V-Xba I-Pvu Ii-Xba I-EcoR V was Inserted at the EcoR I site of pl30-l. The adenovirus type 2 major late promoter and roost of leader 1 were obtained from an adenovirus Sroa I-F clone (27) as an Alu I/Pvu II fragment (position -402 to +33) and Inserted at the newly created Pvu II site 1n pl30-l. Plasmids with the promoter 1n the opposite transcriptional orientation with respect to the p-lactamase gene were selected and designated p506-3.
P506-3 was digested with Pvu II and partially digested with Xho I (at the Xho 1 site downstream of the promoter). A contiguous fragment containing the remainder of leader 1, all of leader 2 and roost of leader 3 was released as a 140 bp Pvu II-Xho I fragment from pJAW43 (28), a cDNA clone of an adenovirus fiber mRNA, and was Introduced Into p506-3. Downstream of leader 3 we Inserted a tandemly repeated element of the structure (GCC) 4 contained within a polylinker unit shown below: Xhol Adaptor (GCC) 4 Nhel Kpnl EcoRI BaraHI EcoRV KNruI This unit was Inserted between the Xho I site, Immediately downstream of leader 3, and the Nru I site 1n p«L2d. The CAT gene was cloned downstream of the GCC repeats 1n two steps. First, an Alu I-EcoR I fragment (14 nucleotides upstream and 214 nudeotides downstream of the CAT translational Initiation codon) was Inserted between the Nae I (at the end of the final GCC) and the EcoR I (within the polylinker) sites.
The remainder of the CAT coding sequence, as well as the downstream SV4O t-spl1ce and polyadenylation sequences [SV40A(A)] was purified from pSV_CAT as an EcoR I-BaraH I fragment and Inserted between the EcoR I and BaraH I sites Immediately downstream of the 5' end of the CAT gene.
pHLP-CAT + Enhancers. Enhancers were Introduced either Immediately upstream of the major late promoter at the EcoR V site (-414 relative to the cap site) or at the NspH I site (-107) within the promoter.
In the latter case, the unique NspH 1 site was made blunt by digesting the 3'-overhang with the combined exonuclease-polyroerase activities of 14 DNA polynerase 1n the presence of deoxynudeotide triphosphates. In both cases vectors with enhancers 1n both orientations were Isolated.
The SV40 enhancer was purified from pSV 2 CAT as a 179 bp Fok I to Pvu II fragment. This fragment contains the two 72 bp repeats and the pur1ne/pyr1m1d1ne 8-mer Important for enhancer activity found Just upstream of the repeats (29, 30) .
The human cytomegalovirus enhancer was purified from pC4 (24) as a 271 bp Tha I/Hnl I fragment. This fragment lacks only 2 bp of cytomegalovirus enhancer at the lha I end and has only 11 bp derived from SV40 DNA at the Mnl I end of the molecule.
The Moloney murine sarcoma virus enhancer extends from the H1nf I (nucleotide no.141) to the Xba I (nucleotide no.525) restriction sites from the proviral LTR (31), with modified BamH I termini as described (22) .
PHSV-MT-CAT. The HSV enhancer 1n combination with the HT promoter was excised from p8-4 (22) using a combined Cla I/Xho I cleavage. Following repair of these sites with Klenow fragment the enhancer-promoter fragment was Inserted at the blunted H1nd III site of pSVoCAT, Just upstream of the CAT coding sequence. Plasnids with the promoter 1n the same transcriptional direction as CAT were selected. Cells and DNA Transfection House C127 (32), 1013 (33). and NS33-7 cells (34) were maintained 1n Oulbecco modified Eagle medium containing 10% fetal bovine serum, penicillin (100 y/ral), streptomycin (100 ug/ral) and glucose (4.5 g/L) (Meloy Laboratories, Inc.). ID13 cells are C127 transformed with full-length BPV DNA. NS33-7 cells harbor BPV DNA, containing a deletion 1n Its late region, linked to pHL2 sequence (26).
DNA transfections were performed using the calcium phosphate co-predp1tat1on method (35) and an enhancement step with 15% glycerol (36) as previously described (22). Between 5-10 v g DNA 1n 500 pi volume was 
RESULTS

Vector Organization
The present study was designed to compare various regulatory elements for optimal recombinant gene expression 1n BPV transformed C127 cells. Three promoters evaluated Include the SV40 early, mouse metalIoth1one1n (NT) and adenovirus type 2 major late (HLP). Enhancers Include those derived from SV40, human cytomegalovirus (HCHV) and Moloney murine sarcoma virus (MSV). The HSV enhancer-HT promoter combination has been extremely effective 1n BPV vectbrs (22) and was used as a reference combination 1n this study. The various vectors used are described 1n Table 1 , and their general configuration 1s diagramed 1n Figure 1 .
In the remainder of this section we will be referring often to the combinations shown 1n this table.
In figure 1 , vector C contains several Important elements. This parental vector, pHLP-CAT has the adenovirus type 2 major late promoter but 
Expression of pMLP-CAT 1s Increased With the Addition of Enhancers
We tested three different enhancers, placed about 400 bp upstream of the cap site for their ability to potentiate the major late promoter 1n 1013 cells. The SV40 enhancer was the roost effective 1n activating CAT expression (Figure 4) . The orientation of the enhancer had minimal effect on the level of activation. The relative Inefficiency of the HCMV enhancer was somewhat unexpected, because 1n conjunction with the SV40 promoter 1t was more efficient 1n these cells (Figure 3) . Thus relative to the SV40 enhancer the effect of the cytomegalovirus enhancer 1s more pronounced on the SV40 promoter than on the adenovirus major late promoter. The HCMV and SV40 enhancers demonstrated opposing cell preference (the HCHV enhancer was more effective 1n BPV transformed cells whereas the SV40 enhancer was more active 1n untransformed C127 cells). However, when these enhancers were each linked to the major late promoter, no clear cell preference was discerned (data not shown).
These results Indicate that the expression of foreign genes 1n BPV-transfortied C127 cells using a BPV shuttle vector may be Increased by replacing the MSV enhancer and MT promoter with an SV40 enhancer and major late promoter. The SV40 enhancer 1n the major late promoter vector Increased CAT activity about 6-fold over the vector without enhancer (pMLP-CAT) (Figure 4). pHLP-CAT had about 60X the activity level of pMSV-NT-CAT 1n ID13 cells (Figure 3). The combined effect of these two values predict a 3-4-fold greater activity level with pSV E~H LP-CAT vector relative to that Induced by the pHSV-HT-CAT vector. In fact, experiments comparing these vectors directly show a 4-5-fold activity differential (data not shown). The Distance of Enhancer From The Promoter Cap Site Affects Expression In a Host Cell Dependent Manner
The distance between an enhancer and the promoter cap site 1s Important for the level of potentiation of transcriptional activity (39,40). We examined the effect of Introducing an enhancer closer to the cap site of the major late promoter. CAT activities Induced by vectors with the SV40 enhancer at either position -107 or at position -414 were compared with activity Induced by the parent vector without enhancer 1n ID13 cells ( Figure  5 ). While the enhancer at -107 was found to Increase the activity of the major late promoter 3-1/2 fold, this potentiation was only 40X of that due to enhancer at -414 which, 1n this experiment, demonstrated a 9-1/2 fold Increase over pMLP-CAT ( Figure 5 ). These averages were found to be different at the 95% confidence level using the t-d1str1but1on. From these data we conclude that the position occupied by an enhancer relative to the promoter cap site modulates expression 1n a cell type specific manner. Further, at these relatively short distances, the proximal position was not necessarily the optimal location for maximal expressional activity. (47) who suggested that the effect was due to non-leader mRNA sequences. A "GCC" repeat sequence has also been Implicated 1n the efficient expression of adenoviral genes during Infection, as suggested by the high level translation of a chimeric mRNA containing this tandem motif 1n addition to leader 1 (38).
The major late promoter vector, pMLP-CAT, was quite active 1n both C127 and 1013 cells even 1n the absence of a linked enhancer. Expression was further augmented with the Introduction of an enhancer element (SV40, HCHV, or HSV) Immediately upstream of the promoter. The SV40 enhancer was consistently the most active of the enhancers studied, stimulating the pMLP-CAT vector by as much as ten fold 1n 1013 cells. Interestingly, the cytoraegalovirus enhancer, found to be stronger than the SV40 enhancer 1n activating the SV40 promoter in 1D13 and NS33-7 cells, was clearly weaker than the SV40 enhancer 1n activating the major late promoter. This Interactive enhancer-promoter effect has been demonstrated 1n several other studies. The SV40 and Harvey sarcoma virus enhancers are capable of activating the 3-glob1n promoter more than the SV40 promoter (5). Moreover, the host cell also plays a major role 1n Influencing the level of expression for a given enhancer-promoter combination. Surprisingly, while the HCHV enhancer showed a cell preference for 1013 and NS33-7 cells over C127 cells when linked to the SV40 promoter, no clear cell preference was seen when 1t Interacted with the major late promoter. This 1s similar to the observation that the SV40 enhancer linked to the Herpes simplex virus thym1d1ne kinase promoter 1s Inactive 1n CVI and Hela cells but active 1n COS-7 cells while the same enhancer linked to the SV40 promoter 1s active 1n all three cell lines (48) . Therefore 1t appears that cell specificity or preference may reflect enhancer-promoter Interactions and not simply enhancer-spedf 1c activities. This complex Interaction Involving enhancer, promoter and cell line may explain why the HSV enhancer 1s weaker than the SV40 enhancer when coupled to the major late promoter In our study, but stronger when acting upon the SV4O promoter (2) 1n several other mouse cell lines.
The translocation of the SV40 enhancer from the -414 position to the -107 position relative to the cap site of the major late promoter resulted 1n a significant decrease of CAT expression in 1013 cells. Similar studies with enhancer and promoter at these distances suggested that the closer proximity of the enhancer to the cap site results 1n an elevation 1n expression (39). These studies, however, differ from our study 1n several respects. For example, while we utilized a complete Ad 2 major late pronoter, those studies used either different promoters or a truncated major late promoter which lacks sequences Important for promoter activity. One possible explanation 1s that In our study the enhancer 1s supplementing activity of a complete major late promoter, while 1n the other studies the enhancer 1s substituting for promoter functions lacking 1n the truncated major late promoter (49) . Another difference 1s that our analysis was performed 1n 1013 cells while HeLa cells were utilized by others. We have shown that the host cell type Influences the effect of the relative position of enhancer and promoter on expression. Significantly, the closer location of the enhancer to the cap site 1s not necessarily the better for optimal expression.
There appear to be two mechanisms by which the major late promoter can be activated; In ds as with the SV40 enhancer or 1n trans as with the Adenovirus Ela protein (50) . Several cellular proteins have been shown associated with the active SV40 enhancer (51) as well as the major late promoter (52, 53, 54, 55) . The efficiency of the enhancer-promoter Interaction with these elements at different distances from each other might well be dependent upon the specific set of associated cellular factors within distinct cell lines.
In our studies to optimize gene expression 1n BPV transformed cells we v have ascribed differential vector activities within the various cell lines to enhancer/promoter specificities by assaying levels of CAT expression. The possibility that these activity differences are due to cell dependent differential transcriptional start sites with post-transcrlptional effects has not been eliminated. In summary our studies of CAT expression directed by a number of enhancer-promoter combinations demonstrate a range of activities. We have shown that the BPV transformation of C127 cells affects the relative activities of the test vectors. As these studies are Intended to Improve activity from the BPV vectors, 1t 1s appropriate that the final comparisons be made 1n BPV transformed cells. Within these cells the roost active vector, composed of the SV40 enhancer 1n conjunction with the adenovirus major late promoter 1s able to express CAT at levels 4-5 fold higher than that of the reference vector containing the reurine sarcoma virus enhancer and metalIoth1one1n promoter. Our findings provide a basis for Improvement of the BPV system. This potential Improvement 1s currently being evaluated. We have provided these vectors to Dr. Darrel Stafford (University of North Carolina, Chapel H111) who 1s testing these vectors for stable expression of human factor IX using the BPV vector system. The feasibility of producing recombinant proteins for clinical use may depend upon such Increased levels of expression.
